Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 1011 - 1020 of 1165

Sylvant (siltuximab)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Multicentric Castleman's Disease (MCD)

Last updated September 30, 2016

Fabrazyme (agalsidase beta)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Fabry Disease

Last updated September 30, 2016

Revlimid (lenalidomide)

Status:

Concluded with an LOI

Manufacturer:

Celgene Inc.

Indication:

Multiple Myeloma (newly diagnosed)

Last updated September 14, 2016

Esbriet (pirfenidone)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Pulmonary fibrosis (idiopathic, mild to moderate)

Last updated September 11, 2016

Ferriprox (deferiprone)

Status:

Concluded with an LOI

Manufacturer:

ApoPharm Inc.

Indication:

Transfusional iron overload due to thalassemia

Last updated September 7, 2016

Ofev (nintedanib)

Status:

Concluded with an LOI

Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

Indication:

Idiopathic pulmonary fibrosis (IPF)

Last updated August 29, 2016

Rosiver (ivermectin)

Status:

Concluded without agreement

Manufacturer:

Galderma Canada Inc.

Indication:

Rosacea

Last updated August 26, 2016

Simponi SC (golimumab)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Ulcerative Colitis

Last updated August 12, 2016

Arnuity Ellipta (fluticasone furoate)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Asthma

Last updated August 8, 2016

Breo Ellipta (fluticasone furoate/vilanterol)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Asthma

Last updated July 11, 2016